B-Lymphocyte Depletion With Rituximab and  -Cell Function: Two-Year Results

Effect of rituximab on human in vivo antibody immune responses

(2011) Mark D. Pescovitz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

B cell-directed therapies in type 1 diabetes

(2011) Eliana Mariño et al.   TRENDS IN IMMUNOLOGY

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

(2009) Pina M. Cardarelli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

(2009) Kevan C. Herold et al.   CLINICAL IMMUNOLOGY

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

(2009) Jorge Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

(2009) Mark D. Pescovitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE